Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
Erlotinib in Combination With Cetuximab
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2015-07-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00895362
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Trial of PM02734 Administered in Combination With Erlotinib in Patients With Advanced Malignant Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2009-04-21
- Last Posted Date
- 2014-03-26
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 35
- Registration Number
- NCT00884845
- Locations
- 🇪🇸
Intituto Universitario Dexeus, Barcelona, Spain
🇪🇸Hospital Universitario Germans Trias i Pujol, Badalona, Barcelona, Spain
🇺🇸Montefiore Medical Center, New York, New York, United States
Individualized Treatment Based on Epidermal Growth Factor Receptor Mutations and Level of BRCA1 Expression in Advanced Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2009-04-17
- Last Posted Date
- 2022-06-13
- Lead Sponsor
- Spanish Lung Cancer Group
- Target Recruit Count
- 153
- Registration Number
- NCT00883480
- Locations
- 🇪🇸
Ico-Hospital Universitarios Germans Trias I Pujol, Badalona, Barcelona, Spain
🇪🇸Hospital Carlos Haya, Málaga, Spain
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
- Conditions
- Interventions
- First Posted Date
- 2009-04-02
- Last Posted Date
- 2014-09-25
- Lead Sponsor
- Tongji University
- Target Recruit Count
- 165
- Registration Number
- NCT00874419
- Locations
- 🇨🇳
Medical Department, Shanghai Pulmonary Hospital, Shanghai, China
A Study of the Combination of Erlotinib and Pertuzumab in Patients With Relapsed Non-small Cell Lung Cancer
- First Posted Date
- 2009-03-05
- Last Posted Date
- 2013-05-21
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 41
- Registration Number
- NCT00855894
A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)
- Conditions
- Interventions
- First Posted Date
- 2009-02-20
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 77
- Registration Number
- NCT00848718
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
- First Posted Date
- 2009-02-13
- Last Posted Date
- 2020-09-29
- Lead Sponsor
- University of California, San Francisco
- Target Recruit Count
- 17
- Registration Number
- NCT00843531
- Locations
- 🇺🇸
University of California, San Francisco, San Francisco, California, United States
7 Day's of Erlotinib Neo-adjuvant, Followed by Adjuvant Erlotinib-gemcitabine in Pancreatic Cancer Patients
- First Posted Date
- 2009-02-11
- Last Posted Date
- 2017-05-19
- Lead Sponsor
- University of Alabama at Birmingham
- Target Recruit Count
- 6
- Registration Number
- NCT00841035
- Locations
- 🇺🇸
University of Alabama at Birmingham,Comprehensive Cancer Center, Birmingham, Alabama, United States
Study of Erlotinib With Docetaxel in Selected Non Small Cell Lung Cancer Patients in First Line Treatment
- First Posted Date
- 2009-02-10
- Last Posted Date
- 2012-10-30
- Lead Sponsor
- Meir Medical Center
- Target Recruit Count
- 4
- Registration Number
- NCT00840125
- Locations
- 🇮🇱
Meir Medical Center, Kfar Saba, Israel
2nd Line Erlotinib Treatment With (Out) Chemotherapy of Advanced Non Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2009-02-03
- Last Posted Date
- 2020-09-29
- Target Recruit Count
- 195
- Registration Number
- NCT00835471
- Locations
- 🇳🇱
VU medisch centrum, Amsterdam, Netherlands
🇳🇱Reinier de Graaf Gasthuis, Delft, Netherlands
🇳🇱Isala Klinieken, Zwolle, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.